Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma 10Neutropenia 8Breast Neoplasms 8Leukemia, Myeloid, Acute 7Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 4Febrile Neutropenia 4Leukemia, Monocytic, Acute 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Osteosarcoma 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Retinoblastoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Tamoxifen 4Exercise 3pyrotinib 2abemaciclib 2Paclitaxel 2Metformin 2Letrozole 2Cyclophosphamide 2Control Groups 2Capecitabine 2Bupivacaine 2Aromatase Inhibitors 2pembrolizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1palbociclib 1iniparib 1exemestane 1durvalumab 1darolutamide 1Yoga 1Waiting Lists 1Vitamin D 1Tumor Burden 1Tretinoin 1Trastuzumab 1Tocopherols 1Thioctic Acid 1Surveys and Questionnaires 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Female × pegylated granulocyte colony-stimulating factor × Clear all
NCT04554056 2022-12-02

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2/3 Completed
586 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡